|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.|
|Rapid review commissioned||16/02/2016|
|Rapid review completed||14/03/2016|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended.|
Not considered cost-effective due to non-submission of full pharmacoeonomic assessment.